First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report

Federica Facchin, Cecilia Alejandra Fontana, Nicola Persico, Giovanna Scarfone, Monica Fumagalli, Martina Imbimbo, Tommaso Ceruti, Fulvia Milena Cribiù, Eugenia Di Loreto, Maurizio D'Incalci, Camilla Fontana, Marina C. Garassino, Fedro A. Peccatori, Massimo Zucchetti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

This is the first case report of a patient with ALK-rearranged metastatic lung adenocarcinoma who became pregnant during treatment with alectinib. A multidisciplinary team of gynecologists, neonatologists, oncologists, psychologists, and pharmacologists was set up to handle the case. According to patient's preference, the study drug was continued throughout pregnancy and the woman delivered a healthy baby girl at 35 weeks and 5 days of gestation. Fetal parameters remained normal during pregnancy. At birth, alectinib levels were 14 times higher in maternal plasma than in the fetus (259 versus 18 ng/mL). The average concentration of alectinib in the placenta was 562 ng/g. The baby was followed during her first 20 months, and no developmental anomalies were observed. After 32 months from diagnosis, the mother is well and in partial remission.
Lingua originaleEnglish
pagine (da-a)873-877
Numero di pagine5
RivistaJournal of Thoracic Oncology
Volume16
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • ALK rearrangement
  • Alectinib
  • Case report
  • Lung cancer
  • Pregnancy

Fingerprint Entra nei temi di ricerca di 'First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report'. Insieme formano una fingerprint unica.

Cita questo